We are live on ! Find out more
DFTX

Definium Therapeutics

88 hedge funds and large institutions have $12.6M invested in Definium Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

879% more call options, than puts

Call options by funds: $9.78M | Put options by funds: $999K

13% more capital invested

Capital invested by funds: $11.1M → $12.6M (+$1.41M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

3.12% less ownership

Funds ownership: 13.48%10.36% (-3.1%)

15% less funds holding

Funds holding: 10488 (-16)

27% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 22

58% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 19

Holders
88
Holders Change
-16
Holders Change %
-15.38%
% of All Funds
1.4%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
16
Reduced
22
Closed
19
Calls
$9.78M
Puts
$999K
Net Calls
+$8.78M
Net Calls Change
+$1.56M

DFTX Hedge Fund Activity: Q1 2023 in Review

88 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q1 2023, worth a combined $12.6M — up 13% from $11.1M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of DFTX and 8 opened new positions — a net loss of 11 holders — while 22 trimmed existing stakes and 16 added.

The largest buyer was Two Sigma Investments, adding an estimated $447K. The largest seller was Merit Financial Group, exiting entirely with an estimated $1.19M sold.

  • 88 institutional investors held Definium Therapeutics (DFTX) as of Q1 2023, down from 104 in Q4 2022.
  • Funds reported $12.6M of Definium Therapeutics stock for Q1 2023, up 13% quarter-over-quarter.
  • 8 funds opened new Definium Therapeutics positions in Q1 2023 and 19 closed out, a net change of -11 holders.
  • The largest Definium Therapeutics buyer in Q1 2023 was Two Sigma Investments, an estimated $447K added.
  • The largest Definium Therapeutics seller in Q1 2023 was Merit Financial Group, an estimated $1.19M sold.

Based on aggregated 13F filings for Q1 2023.